Physician profile
Steve Flinkenstein
NPI 1821209255
$2,034.30
in general payments reported to CMS, 2019-2025
22 companies · $687 in 2025
The $687 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $667 · 2024: $557 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.94 |
| Education | $143.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $287.89 | 2022-2025 | Tremfya, Simponi Aria |
| Amgen INC. | $268.67 | 2022-2025 | Evenity, Enbrel, Tavneos |
| Mallinckrodt Hospital Products INC. | $228.20 | 2023-2024 | Acthar |
| Pfizer INC. | $217.24 | 2022-2025 | |
| Abbvie INC. | $194.12 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $150.58 | 2023-2024 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $150.55 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $69.62 | 2023-2025 | Saphnelo |
| Fresenius Kabi USA, LLC | $69.02 | 2024 | Idacio |
| Alexion Pharmaceuticals, INC. | $64.29 | 2023-2025 | Strensiq, Ultomiris |
| Glaxosmithkline, LLC. | $52.23 | 2023-2024 | Benlysta |
| Genentech USA, INC. | $45.55 | 2024-2025 | Actemra |
| Ucb, INC. | $41.95 | 2024 | Cimzia |
| Lilly USA, LLC | $32.73 | 2023-2025 | Taltz |
| Organon LLC | $27.64 | 2024-2025 | Hadlima |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $22.58 | 2024 | Teriparatide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.94 | 2024 | Cyltezo |
| Sobi, INC | $20.34 | 2024 | |
| Genzyme Corporation | $19.86 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $19.23 | 2022 | |
| Horizon Therapeutics Plc | $17.87 | 2023 | Krystexxa |
| Teva Pharmaceuticals USA, INC. | $13.20 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Flinkenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.